13:00 Tue 10 Aug 2021
RUA Life Sciences - Directorate Change
RUA Life Sciences plc
("RUA Life Sciences", the "Company" or the "Group")
Directorate Change
Withdrawal of Annual General Meeting (AGM) Resolution
RUA Life Sciences (AIM:RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM), announces the following board changes and plans for further senior management recruitment.
David's technical knowledge and product innovation expertise will remain available to the Group as he will provide consultancy services to the Group and the Research and Development team in particular.
The Company is pleased to announce that Dr
Caroline was recruited in
In addition,
RUA Life Sciences intends to further strengthen its senior management team by recruiting for a newly created role of Head of Clinical and Regulatory Affairs together with a Chief Financial Officer/Finance Director, for which search processes are currently being undertaken and details of the successful candidates will be announced in due course.
In light of
For further information contact:
RUA Life Sciences
David Richmond, CEO Tel: +44 (0)1294 317073
Shore Capital (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7408 4080
Tom Griffiths/David Coaten
Cenkos Securities plc (Joint Broker) Tel: +44 (0)20 7397 8900
Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane.
Whether it is licensing Elast-EonTM, manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
RUA Medical: |
End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist. |
RUA Biomaterials: |
Licensor of Elast-EonTM polymers to the medical device industry.
|
RUA Vascular: |
Development of large bore polymer sealed grafts and soft tissue patches.
|
RUA Structural Heart: |
Development of tri leaflet polymeric heart valves. |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE